100
Participants
Start Date
June 1, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
August 31, 2026
TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir
Dolutegravir, lamivudine and tenofovir disoproxil fumarate tablets, a combination of dolutegravir (integrase strand transfer inhibitor \[INSTI\]), lamivudine, and tenofovir disoproxil fumarate (both nucleoside reverse transcriptase inhibitors), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg
Ezintsha, a division of Wits Health Consortium, Johannesburg
Africa Health Research Institute (AHRI), Durban
Desmond Tutu Health Foundation, Cape Town
Bill and Melinda Gates Foundation
OTHER
University of Witwatersrand, South Africa
OTHER